Who is Using Chronic Acid Suppression Therapy and Why?

Department of Medicine, Gastroenterology Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
The American Journal of Gastroenterology (Impact Factor: 10.76). 01/2003; 98(1):51-8. DOI: 10.1111/j.1572-0241.2003.07186.x
Source: PubMed


Acid suppression medications have become one of the most commonly prescribed classes of therapeutic agents. Because little data exists describing the chronic use of these agents among a general population, we sought to determine the patterns of use of proton pump inhibitors (PPIs) and histamine type 2 receptor antagonists (H2RAs) in clinical practice, as well as the distribution and severity of symptoms in patients prescribed these therapies.
Pharmacy billing data from two insurers were used to identify all patients on chronic (>90 days) PPIs and H2RAs within a large, eastern Massachusetts provider network. Patient demographics, diagnoses, frequency of office visits, and information about diagnostic testing were obtained from billing databases. A questionnaire addressing recent upper GI symptoms, over-the-counter medication use, and gastroenterologist consultations was mailed to a 1,139 patient subset (35%) of eligible patients. We compared the diagnoses of patients on chronic therapy with those of the general population of the network. We also compared the frequency of symptoms and diagnostic testing between those prescribed H2RAs and PPIs.
From a total population of 168,727 adult patients, we identified 4,684 (2.8%) prescribed chronic acid suppression therapy, with 47% taking H2RAs and 57% taking PPIs (4% filled prescriptions for both simultaneously). A relevant GI diagnosis was found using billing data for only 61% of patients, mainly for gastroesophageal reflux disease (38%) and dyspepsia (42%), with many patients carrying both diagnoses. Our survey (response rate 59%) revealed that more than 30% of responders experienced heartburn or reflux more than twice a week, and more than half experienced symptoms of dyspepsia at least once a week. Diagnostic testing was uncommon, with only 19% having undergone esophagogastroduodenoscopy within the prior 2 yr.
Acid suppression medications were used chronically by a large number of patients within this population. A significant proportion of patients on chronic PPI or H2RA lacked definitive upper GI diagnoses in their billing data. The high symptom burden and low use of diagnostic testing indicates opportunities for improvement in the care of patients on chronic acid suppression therapy.

15 Reads
  • Source
    • "There is no consensus or agreed defi nition on what constitutes long term PPIs prescription. The defi nition has varied: from one repeated prescription over 12 months to continuous therapy for periods ranging from 4 to >12 months (Table 1) (Ryder et al 1994; Roberts and Bateman 1995; Rubin et al 1995; Goudie et al 1996; Ahnfeldt-Mollerup et al 1997; Boutet et al 1999; Hungin et al 1999; Prach et al 1999; Vetvik and Straand 2001; Hurenkamp et al 2002; Chen et al 2003; Jacobson et al 2003; Majumdar et al 2003; Lassen et al 2004; Raghunath and Hungin 2004; Tsai et al 2004; Raghunath et al 2005). GERD is a very common complaint when considering the management of treatment with PPIs in the population over 65 years of age. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of gastroesophageal reflux disease (GERD) increases with age and elderly are more likely to develop severe disease. Older patients often complain of less severe or frequent heartburn than younger patients and they may present with atypical symptoms such as dysphagia, weight loss, or extraesophageal symptoms. Proton pump inhibitors (PPIs) are central in the management of GERD and are unchallenged with regards to their efficacy. They are considered safe and more effective than histamine receptor antagonists for healing esophagitis and for preventing its recurrence using a long term maintenance treatment. PPI have minimal side effects and few slight drug interactions and are considered safe for long term treatment. Pantoprazole is significantly effective both for acute and long-term treatment with excellent control of relapse and symptoms. It is well tolerated even for long-term therapy and its tolerability is optimal. Pantoprazole shows to have minimal interactions with other drugs because of a lower affinity for cytocrome P450 than older PPIs. Although the majority of elderly has concomitant illnesses and receive other drugs, this does not adversely effect the efficacy of pantoprazole because of its pharmacokinetics, which are independent of patient age. Clinical practice suggests that a low dose maintenance of PPIs should be used in older patients with GERD.
    Full-text · Article · Feb 2007 · Clinical Interventions in Aging
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Las hemorragias intestinales son causa importante de internamiento hospitalario y muerte, siendo significativamente relevante en pacientes críticamente debilitados y con artritis reumatoide y osteoartritis que usan antiinflamatorios no esteroídicos (AINE). El omeprazol es el medicamento de elección para profilaxis de úlcera de estrés, prevención de complicaciones relativas a los AINE, ya que previene tanto de la úlcera duodenal como gástrica y la erradicación del H pylori junto con antibióticos. El objetivo de este estudio fue determinar la frecuencia, indicaciones de uso y características de la población usuaria de omeprazol. Se realizó un estudio de utilización de medicamentos cualitativo y cuantitativo. La población estuvo constituida por adultos internados en un Hospital Universitario. De los 91 pacientes estudiados, la mayoría (24,2%) tenía cáncer. El tiempo medio de internamiento y uso del omeprazol fue de 20 y 12 días respectivamente. El equipo de cirugía abdominal fue el que más prescribió el medicamento, y la principal indicación de uso fue en el post-operatorio quirúrgico. Aunque la mayoría de las indicaciones para el uso del omeprazol haya sido aceptable, estas podrían estar mejor evaluadas. Sería recomendable la implantación de un programa de atención farmacéutica y la creación de un protocolo de utilización de omeprazol con el fin de prescribir el medicamento de forma racional y adecuada para cada paciente.
    Full-text · Article ·
  • Source

    Full-text · Article ·
Show more